211 related articles for article (PubMed ID: 729215)
1. Comparative studies on the effect of hemoperfusion and hemodialysis on the elimination of some uremic toxins.
Trznadel K; Walasek L; Kidawa Z; Lutz W
Clin Nephrol; 1978 Dec; 10(6):229-31. PubMed ID: 729215
[TBL] [Abstract][Full Text] [Related]
2. Intradialytic changes of serum magnesium and their relation to hypotensive episodes in hemodialysis patients on different dialysates.
Elsharkawy MM; Youssef AM; Zayoon MY
Hemodial Int; 2006 Oct; 10 Suppl 2():S16-23. PubMed ID: 17022745
[TBL] [Abstract][Full Text] [Related]
3. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
4. Solute, amino acid, and hormone changes with coated charcoal hemoperfusion in uremia.
Winchester JF; Ratcliffe JG; Carlyle E; Kennedy AC
Kidney Int; 1978 Jul; 14(1):74-81. PubMed ID: 682427
[TBL] [Abstract][Full Text] [Related]
5. The optimal timing of hemoperfusion component in combined hemodialysis-hemoperfusion treatment for uremic toxins removal.
Li J; Li D; Xu Y; Wang A; Xu C; Yu C
Ren Fail; 2015 Feb; 37(1):103-7. PubMed ID: 25421427
[TBL] [Abstract][Full Text] [Related]
6. Sorbent recycling of ultrafiltrate in man--a 45-week crossover study.
Shapiro WB; Schilb TP; Porush JG
Clin Nephrol; 1986; 26 Suppl 1():S47-52. PubMed ID: 3829468
[TBL] [Abstract][Full Text] [Related]
7. Combined hemodialysis-hemoperfusion treatment reduces the time of substitutive therapy in chronic uremia.
Stefoni S; Feliciangeli G; Coli L; Scolari MP; Bonomini V
Int J Artif Organs; 1981 Jul; 4(4):186-91. PubMed ID: 7327760
[TBL] [Abstract][Full Text] [Related]
8. Effect of blood purification on plasma levels of intact parathyroid hormone in patients with chronic renal failure.
Liu J; Liu ZQ; Tao HQ
Di Yi Jun Yi Da Xue Xue Bao; 2004 Feb; 24(2):234-5. PubMed ID: 14965840
[TBL] [Abstract][Full Text] [Related]
9. [Correction of the composition of the dialyzing solution during its electrochemical regeneration].
Maksimov EP; Leshchinskiĭ GM; Grinval'd VM; Fomicheva NN; Shadiev BSh
Med Tekh; 2003; (2):8-10. PubMed ID: 12924213
[TBL] [Abstract][Full Text] [Related]
10. The dynamics of serum myoinositol concentration changes during haemodialysis and peritoneal dialysis.
Trznadel K; Walasek L; Waldemar L
Acta Med Pol; 1977; 18(1):55-61. PubMed ID: 855681
[No Abstract] [Full Text] [Related]
11. [The effect of hemodialysis and continuous ambulatory peritoneal dialysis on renal anemia].
Stojimirović B; Grujić-Adanja G
Srp Arh Celok Lek; 1997; 125(5-6):163-7. PubMed ID: 9265238
[TBL] [Abstract][Full Text] [Related]
12. Chronic renal disease patients with severe star fruit poisoning: hemoperfusion may be an effective alternative therapy.
Chen LL; Fang JT; Lin JL
Clin Toxicol (Phila); 2005; 43(3):197-9. PubMed ID: 15902795
[TBL] [Abstract][Full Text] [Related]
13. Our experience with combined hemodialysis-hemoperfusion treatment in chronic uremia.
Splendiani G; Albano V; Tancredi M; Daniele M; Pignatelli F
Biomater Artif Cells Artif Organs; 1987; 15(1):175-81. PubMed ID: 3449135
[TBL] [Abstract][Full Text] [Related]
14. [A comparison of the efficiency of eliminating middle-weight molecules and myoinositol from plasma during hemoperfusion and hemodialysis in cases of chronic uremia].
Trznadel K; Kidawa Z; Walasek L; Lutz W
Pol Tyg Lek; 1978 Feb; 33(7):257-9. PubMed ID: 758030
[No Abstract] [Full Text] [Related]
15. [The effect of hemoperfusion through activated charcoal on middle molecular substances in the plasma during a long-term dialysis program].
Mydlík M; Dzúrik R; Derzsiová K; Spustová V
Cas Lek Cesk; 1983 Dec; 122(51):1573-6. PubMed ID: 6652672
[No Abstract] [Full Text] [Related]
16. [Effect of hemodialysis and hemosorption on blood serum level of medium-molecular components in patients with chronic renal failure].
Kozlov VV; Riabov SI; Dorofeeva TB; von Appen K; Spiridonov VN
Ter Arkh; 1984; 56(7):77-81. PubMed ID: 6484840
[No Abstract] [Full Text] [Related]
17. Paraoxonase-1 concentrations in end-stage renal disease patients increase after hemodialysis: correlation with low molecular AGE adduct clearance.
Gugliucci A; Mehlhaff K; Kinugasa E; Ogata H; Hermo R; Schulze J; Kimura S
Clin Chim Acta; 2007 Feb; 377(1-2):213-20. PubMed ID: 17118352
[TBL] [Abstract][Full Text] [Related]
18. Changes in plasma concentrations of hypoxanthine and uric acid before and after hemodialysis.
Shahbazian H; Zand Moghadam A; Ehsanpour A; Khazaali M
Iran J Kidney Dis; 2009 Jul; 3(3):151-5. PubMed ID: 19617664
[TBL] [Abstract][Full Text] [Related]
19. [Initial results in the treatment with short-term dialysis].
Dogliani M; Jeantet A; Coppo R; Canavese C; Camussi G; Giacchino F; Pacitti A
Minerva Med; 1976 Jul; 67(35):2282-8. PubMed ID: 951050
[TBL] [Abstract][Full Text] [Related]
20. [Blood viscosity and the erythrocyte charge in patients with chronic kidney failure and suppurative intoxication and during the correction of these conditions by hemosorption and hemodialysis].
Samoĭlov MV; Zakharchenko VN; Larionov SM; Naumov AG; Danilkov AP; Zakharova VD; Ivleva AI; Kudriavtsev IuV; Surikova TP
Urol Nefrol (Mosk); 1993; (4):34-7. PubMed ID: 8310565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
